AROMICS is a biotech company committed to the discovery and development of novel drugs and diagnostic methods to target relevant human diseases and improve patient’s quality of life.

We believe that OMIC technologies represent an important first step towards gaining biological insights into:

  • How drugs work, giving them added value, reducing attrition rates and advancing  through the clinic.
  • Determining clinically predictive molecular endpoints that help physicians manage the disease, drive prescriptions and monitor drug response.


06/03/2020 | Aromics advances at E-Forum Health 2020
Dr. Carme Plasencia, CEO of Aromics, will present the advances on Bermes Project... More

06/09/2020 | E-pitch Healthcare Forum
Aromics selected among the eight companies participating in the E-pitch Investor... More


01/12/2021 | Aromics selected at the program of EIT Health investor network
As part of the strategy to attract investment for the clinical development of... More

12/09/2020 | Our CEO, Dr Carmen Plasencia, second finalist at the EUTOP50 2020 awards in the Deep Technology category
Dr. Carmen Plasencia, CEO of AROMICS has been the second finalist in the prestigious... More